HomeInsightsStock Comparison

Kopran Ltd vs Lincoln Pharmaceuticals Ltd Stock Comparison

Kopran Ltd vs Lincoln Pharmaceuticals Ltd Stock Comparison

Last Updated on: Jun 06, 2025

Key Highlights

  • The Latest Trading Price of Kopran Ltd is ₹ 193.45 as of 06 Jun 16:01.
  • The P/E Ratio of Kopran Ltd changed from 5.2 on March 2020 to 24.5 on March 2024 . This represents a CAGR of 36.34% over 5 yearsThe P/E Ratio of Lincoln Pharmaceuticals Ltd changed from 5.2 on March 2020 to 12.6 on March 2024 . This represents a CAGR of 19.36% over 5 years.
  • The Market Cap of Kopran Ltd changed from ₹ 109.65 crore on March 2020 to ₹ 1245 crore on March 2024 . This represents a CAGR of 62.59% over 5 yearsThe Market Cap of Lincoln Pharmaceuticals Ltd changed from ₹ 267.6 crore on March 2020 to ₹ 1172 crore on March 2024 . This represents a CAGR of 34.38% over 5 years.
  • The revenue of Kopran Ltd for the Mar '25 is ₹ 175.62 crore as compare to the Dec '24 revenue of ₹ 166.41 crore. This represent the growth of 5.53% The revenue of Lincoln Pharmaceuticals Ltd for the Mar '25 is ₹ 161.3 crore as compare to the Dec '24 revenue of ₹ 155.52 crore. This represent the growth of 3.72%.
  • The ebitda of Kopran Ltd for the Mar '25 is ₹ 20.35 crore as compare to the Dec '24 ebitda of ₹ 20.01 crore. This represent the growth of 1.7% The ebitda of Lincoln Pharmaceuticals Ltd for the Mar '25 is ₹ 19.84 crore as compare to the Dec '24 ebitda of ₹ 32.63 crore. This represent the decline of -39.2%.
  • The net profit of Kopran Ltd changed from ₹ 2.77 crore to ₹ 9.68 crore over 8 quarters. This represents a CAGR of 86.94% The net profit of Lincoln Pharmaceuticals Ltd changed from ₹ 19.01 crore to ₹ 11.58 crore over 8 quarters. This represents a CAGR of -21.95% .
  • The Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 41.75 % on March 2024 . This represents a CAGR of -6.78% over 4 yearsThe Dividend Payout of Lincoln Pharmaceuticals Ltd changed from 6.13 % on March 2020 to 3.86 % on March 2024 . This represents a CAGR of -8.84% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Kopran Ltd

  • Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises.
  • The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment.
  • It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin.
  • Kopran also makes penicillin-G acylase, an enzyme made through fermentation.
  • It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities.

About Lincoln Pharmaceuticals Ltd

  • Lincoln Pharmaceuticals Limited, promoted by Mahendra G Patel, Rajnikant G Patel and Hasmukhbhai I Patel, as a Partnership Firm in January, 1979 to manufacture pharmaceutical formulations was converted into a Public Limited Company in Jan. '95.
  • All the assets and business of the erstwhile partnership were transferred to the Company.
  • The Company is engaged in the business of manufacturing and trading of pharmaceutical products.
  • The focused area includes anti-infective, respiratory system, gynecology, cardio & CNS, anti-diabetic, anti malaria, among others. The Company, incorporated in January, 1995, was carrying on its business by getting its products manufactured on loan licence basis from 1979 to 1982.
  • It then set up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups and, ointments.

Kopran Ltd News Hub

News

Board of Kopran recommends final dividend

Kopran announced that the Board of Directors of the Company at its meeting held on 15 May ...

Read more

15 May 2025 16:01

News

Kopran to hold board meeting

Kopran will hold a meeting of the Board of Directors of the Company on 15 May 2025. Powere...

Read more

07 May 2025 14:37

News

Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly

The United States Food and Drug Administration (USFDA) recently carried out a surveillance...

Read more

28 Apr 2025 15:03

News

Kopran to declare Quarterly Results

Kopran will hold a meeting of the Board of Directors of the Company on 11 February 2025. P...

Read more

05 Feb 2025 12:53

News

Kopran allots 36,200 equity shares under ESOP

Kopran has allotted 36,200 equity shares under ESOP on 21 January 2025. With this allotmen...

Read more

21 Jan 2025 18:36

News

Kopran to discuss results

Kopran will hold a meeting of the Board of Directors of the Company on 13 November 2024 Po...

Read more

06 Nov 2024 14:37

Lincoln Pharmaceuticals Ltd News Hub

News

Board of Lincoln Pharmaceuticals recommends final dividend

Lincoln Pharmaceuticals announced that the Board of Directors of the Company at its meetin...

Read more

22 May 2025 18:24

News

Lincoln Pharmaceuticals to declare Quarterly Results

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 22...

Read more

16 May 2025 14:05

News

Lincoln Pharmaceuticals to announce Quarterly Result

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13...

Read more

07 Feb 2025 10:32

News

Lincoln Pharmaceuticals announces board meeting date

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14...

Read more

07 Nov 2024 14:08

News

Lincoln Pharmaceuticals AGM scheduled

Lincoln Pharmaceuticals announced that the Annual General Meeting (AGM) of the company wil...

Read more

03 Sep 2024 17:11

News

Lincoln Pharmaceuticals to conduct AGM

Lincoln Pharmaceuticals announced that the Annual General Meeting (AGM) of the company wil...

Read more

03 Sep 2024 11:39

SWOT Analysis Of Lincoln Pharmaceuticals Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Kopran Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Lincoln Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Kopran Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Kopran Ltd and Lincoln Pharmaceuticals Ltd

Which company has a larger market capitalization, Kopran Ltd or Lincoln Pharmaceuticals Ltd?

Market cap of Kopran Ltd is 936 Cr while Market cap of Lincoln Pharmaceuticals Ltd is 1,146 Cr

What are the key factors driving the stock performance of Kopran Ltd and Lincoln Pharmaceuticals Ltd?

The stock performance of Kopran Ltd and Lincoln Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kopran Ltd and Lincoln Pharmaceuticals Ltd?

As of June 6, 2025, the Kopran Ltd stock price is INR ₹193.85. On the other hand, Lincoln Pharmaceuticals Ltd stock price is INR ₹572.15.

How do dividend payouts of Kopran Ltd and Lincoln Pharmaceuticals Ltd compare?

To compare the dividend payouts of Kopran Ltd and Lincoln Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions